These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 24501284)

  • 1. IPI-145 shows promise in CLL patients.
    Cancer Discov; 2014 Feb; 4(2):136. PubMed ID: 24501284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia.
    Vangapandu HV; Jain N; Gandhi V
    Expert Opin Investig Drugs; 2017 May; 26(5):625-632. PubMed ID: 28388280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duvelisib for the treatment of chronic lymphocytic leukemia.
    Frustaci AM; Tedeschi A; Deodato M; Zamprogna G; Cairoli R; Montillo M
    Expert Opin Pharmacother; 2020 Aug; 21(11):1299-1309. PubMed ID: 32292084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma.
    Patel K; Danilov AV; Pagel JM
    Blood; 2019 Nov; 134(19):1573-1577. PubMed ID: 31554637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transient hypophysitis in a patient treated by duvelisib for chronic lymphocytic leukemia.
    Orioli L; Sarti K; Van Den Neste E; Maiter D
    Ann Hematol; 2017 Apr; 96(4):685-686. PubMed ID: 28150013
    [No Abstract]   [Full Text] [Related]  

  • 6. Idelalisib for chronic lymphocytic leukemia.
    Brown JR
    Clin Adv Hematol Oncol; 2014 Dec; 12(12):846-8. PubMed ID: 25674842
    [No Abstract]   [Full Text] [Related]  

  • 7. Management of advanced chronic lymphocytic leukemia.
    Cao TM; Coutre SE
    Curr Hematol Rep; 2003 Jan; 2(1):65-72. PubMed ID: 12901156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New European approval: Duvelisib - relapsed/refractory CLL and follicular lymphoma].
    Fornero L; Lamure S
    Bull Cancer; 2021 Oct; 108(10):906-907. PubMed ID: 34607678
    [No Abstract]   [Full Text] [Related]  

  • 9. Promising results Halt phase III studies of idelalisib.
    Inman S
    Am J Manag Care; 2014 Feb; 20(2 Spec No.):E9. PubMed ID: 25764575
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
    Robak T
    Transfus Apher Sci; 2005 Feb; 32(1):33-44. PubMed ID: 15737872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in the treatment of B-cell chronic lymphocytic leukemia.
    Cheson BD
    Oncology (Williston Park); 1990 Sep; 4(9):71-8, 83-4; disc. 84, 87-8, 90 pass. PubMed ID: 2145022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3K-δ inhibitor produces long-lasting responses.
    Cancer Discov; 2013 Jul; 3(7):OF11. PubMed ID: 23847354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
    Dennie TW; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bendamustine: a new treatment option for chronic lymphocytic leukemia.
    Glode AE; Jarkowski A
    Pharmacotherapy; 2009 Nov; 29(11):1375-84. PubMed ID: 19857152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.
    Giannopoulos K; Mertens D; Stilgenbauer S
    Expert Opin Pharmacother; 2011 Dec; 12(18):2857-64. PubMed ID: 22098228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idelalisib Bolsters CLL Regimen.
    Leslie M
    Cancer Discov; 2016 Mar; 6(3):OF2. PubMed ID: 26772993
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeting the microenvironment in chronic lymphocytic leukemia offers novel therapeutic options.
    Audrito V; Vaisitti T; Serra S; Bologna C; Brusa D; Malavasi F; Deaglio S
    Cancer Lett; 2013 Jan; 328(1):27-35. PubMed ID: 22910767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCL-2 inhibitor yields high response in CLL and SLL.
    Cancer Discov; 2014 Feb; 4(2):OF5. PubMed ID: 24501317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status and future directions of clinical trials in chronic lymphocytic leukemia.
    Nerenstone SR; Archer JI; Cheson BD
    Oncology (Williston Park); 1987 Oct; 1(8):31-40, 44. PubMed ID: 3079490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.